jump to navigation

Dr. Curt Bilby, Monday, 2-17-14 February 18, 2014

Posted by The Space Show in Uncategorized.
Tags: , , , , , , , , , , , , , , , , , ,
add a comment

Dr. Curt Bilby, Monday, 2-17-14

http://archived.thespaceshow.com/shows/2189-BWB-2014-02-17.mp3

Guest:  Dr. Curt Bilby.  Topics:  Update on developing RLIP 76 as a radiation countermeasure drug as we as for possible use in space.  Please direct all comments and questions regarding Space Show programs/guest(s) to the Space Show blog, https://thespaceshow.wordpress.com.  Comments and questions should be relevant to the specific Space Show program. Written Transcripts of Space Show programs are a violation of our copyright and are not permitted without prior written consent, even if for your own use. We do not permit the commercial use of Space Show programs or any part thereof, nor do we permit editing, YouTube clips, or clips placed on other private channels & websites. Space Show programs can be quoted, but the quote must be cited or referenced using the proper citation format. Contact The Space Show for further information. In addition, please remember that your Amazon purchases can help support The Space Show/OGLF. See www.onegiantleapfoundation.org/amazon.htm.

We welcomed back Dr. Curt Bilby, CEO of Terapio ( http://terapio.com), to update us on progress with the radiation countermeasure drug RLIP 76, including its potential use to combat and reduce space radiation risks.  We had a one hour update with Dr. Bilby which started with the basics of RLIP 76 which is a naturally occurring protein in the human body.  Dr. Bilby went through the basics with us, told us that since he was last on the show, they have stabilized the shelf life of the product by being able to store it as a white powder and then when needed mix it with saline.  He described the pathway in the body by which RLIP 76 works which is really a supplement to what the body already produces.  We talked about their experimentation and testing under what is known as the FDA Animal Rule which he explained in detail to us.  He also talked about toxicology studies as well as the type of radiation used in testing the product by the independent testing labs at the University of Indiana and Maryland under the management of the NIH.  We discussed the potential uses for RLIP 76 which are prioritized for first responders and those injured but it does have a potential application for space.  Listeners asked our guest several questions about its potential use in space, on the way to Mars, on the surface of Mars, and even on the lunar surface for a lunar settlement.  At one point later in our discussion, I suggested that being able to use RLIP 76 on a lunar settlement a decade or so out might be the first use of it if we escape a nuclear accident, nuclear terrorist attack, etc.  He said such a first usage would be a dream come through as it would mean there were no nuke accidents or attacks and we had a settlement on the Moon!  We did talk at length about the two types of animals used in the testing, plus moving to human trials and what information is sought from the human trials.  We also talked about production and manufacturing for RLIP 76 and I asked if they had future plans for outsourcing the production to another country.  Near the end of our discussion, Dr. Bilby went through the four phases of testing with us as required by the FDA. We also talked extensively about the FDA Emergency Use Authorization for any drug and a listener wanted to know if a Mars mission could apply & be approved for using RLIP 76 as part of their life support mission planning.  Just as the show ended, Doug sent in an email asking about the probability of NASA increasing the amount of radiation allowed if the crews used RLIP 76.  Dr. Bilby answered him by saying pharmaceuticals might change the profile & exposure levels as current standards are for unmedicated crews.  But it was far from certain & NASA might not be the determining agency on the matter.

Post your comments/questions on TSS Blog.  You can contact Dr. Bilby through me or his website.

Dr. Curt Bilby, Dr. Elizabeth Leffel, Monday, 10-22-12 October 23, 2012

Posted by The Space Show in Uncategorized.
Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
add a comment

Dr. Curt Bilby, Dr. Elizabeth Leffel, Monday, 10-22-12

http://archived.thespaceshow.com/shows/1878-BWB-2012-10-22.mp3

Guests: Dr. Curt Bilby, Dr. Elizabeth Leffel.  Topics:  The RLIP76 protein by Terapio for radiation toxicity mitigation from multiple causes.  You are invited to comment, ask questions, and discuss the Space Show program/guest(s) on the Space Show blog, https://thespaceshow.wordpress.com. Comments, questions, and any discussion must be relevant and applicable to Space Show programming. Written Transcripts of Space Show programs are not permitted without prior written consent from The Space Show (even if for personal use) & are a violation of the Space Show copyright. We do not permit the commercial use of any Space Show program or part thereof, nor do we permit Space Show programs to be edited, placed on YouTube, or other private channels & websites. Space Show programs can be quoted in news articles, papers, academic & research work, but must be cited or referenced using the proper citation format. Contact Dr. Livingston for questions about our copyright and trademark policies.  We welcomed Drs. Curt Bilby & Elizabeth Leffel to the program to discuss the use of the RLIP76 protein for radiation damage mitigation using this biologic medical product.  You can learn much more about RLIP76 at the Terapio website, www.terapio.com. Terapio won Honorable Mention at this year’s NewSpace Business Plan Competition where I met Dr. Leffel as she presented for the company at the competition. You can see Dr. Leffel’s presentation at www.spacevidcast.com/2012/07/27/newspace-2012-business-plan-competition-part-2.  Dr. Leffel starts her presentation at 26 minutes 25 seconds into the video. In starting today’s discussion, our guests explained RIP76 and how it works through the oxidative stress pathway.  We learned about the FDA Animal Rule being used given human radiation experiments are not allowed.  We also talked about FDA fast tracking RLIP76 approval in case of an emergency, plus how RLIP76 would probably be used for acute radiation syndrome as compared to a chronic radiation exposure as the treatment models differ.  Near the end of the first segment, NYC 1st responder Daniel called us with several questions applicable to his being an emergency 1st responder & likely to be closely involved in any nuclear terrorist event. We don’t often get a view of this world on The Space Show so I urge you to pay attention to Daniel’s questions & the discussion with our guests.

In our second segment, I asked Dr. Bilby questions about the venture capital model for pharmaceutical R&D, pricing, & national healthcare systems plus insurance companies blocking access to many of these cutting edge drugs due to their high cost.  Curt took us through the risks associated with the different stages of pharmaceutical R&D, clinical trials, & product distribution. We talked about the very high failure rate for new drug research & we were introduced to the term “valley of death” as applied to this process.  We talked more about the actual RLIP76 process, potential pricing of the product & public health policy that might control its use.  We had a caller ask about using RLIP76 on a one way Mars trip as a trial, wondering if the FDA would approve such an “experiment.”  Dr. Bilby explained why it was unlikely this would happen, then we talked about getting RLIP76 for a space use by going outside the U.S.  Listen to why that won’t work. We also talked about space radiation issues, the possible role of RLIP76 regarding these issues, plus NASA’s interest in working with Terapio in their research.  Doug called to cite Terapio as a perfect example of a space scalable business, a topic we talk often of on The Space Show. As the segment ended, I asked Dr. Bilby if Terapio was public or if it had plans to do an IPO anytime in the near future. He explained the mixture of government & private sector equity partners but no plans for an IPO at this time.

Please post your comments/questions on The Space Show blog.  You can email our guests through me.